Auteri A, Blardi P, Celasco G, Segre G, Urso R
Institute of Clinical Medicine, University of Siena, Italy.
Int J Clin Pharmacol Res. 1992;12(3):129-32.
The pharmacokinetics of pramiracetam was assessed using an HPLC method after oral administration of two different formulations of 600 mg (a solution and a tablet) of pramiracetam to 11 fasting volunteers. The mean kinetic parameters were: t1 = 4.7 +/- 2.4 - 4.3 +/- 2.2 h, AUC = 57.6 +/- 43.6 - 47.2 +/- 33.9 micrograms h/ml, Cmax = 6.80 +/- 3.2 - 5.80 +/- 3.3 micrograms/ml for the solution and the tablet respectively. The plasma profile of pramiracetam proved to be not highly affected by the formulation, only that the absorption rate was faster after oral administration of the drug in solution than after administration as a tablet. The half-life was very variable between subjects [2-8 hours], but less variable within subjects and it was unaffected by the formulation.
采用高效液相色谱法，对11名空腹志愿者口服600毫克两种不同剂型（溶液剂和片剂）的普拉西坦后的药代动力学进行了评估。平均动力学参数如下：溶液剂和片剂的t1分别为4.7±2.4 - 4.3±2.2小时，AUC分别为57.6±43.6 - 47.2±33.9微克·小时/毫升，Cmax分别为6.80±3.2 - 5.80±3.3微克/毫升。结果表明，普拉西坦的血浆曲线受剂型影响不大，只是口服溶液剂后药物的吸收速度比片剂快。半衰期在受试者之间变化很大（2 - 8小时），但在个体内变化较小，且不受剂型影响。
